Biosimilar drug makers settle IP spat over arthritis drug Humira
Intellectual Property January 21, 2020 2:21 pm By Christine Caulfield | Melbourne

German drug company Fresenius Kadi has resolved a patent case brought by Korean drug company Samsung Bioepis over a biosimilar of top selling arthritis drug […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.